See more : SinoMab BioScience Limited (3681.HK) Income Statement Analysis – Financial Results
Complete financial analysis of AVEO Pharmaceuticals, Inc. (AVEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVEO Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- 4Sight Holdings Limited (4SI.JO) Income Statement Analysis – Financial Results
- Strike Energy Limited (STX.AX) Income Statement Analysis – Financial Results
- Oxford Square Capital Corp. (OXSQ) Income Statement Analysis – Financial Results
- Ebang International Holdings Inc. (EBON) Income Statement Analysis – Financial Results
- OYO Corporation (9755.T) Income Statement Analysis – Financial Results
AVEO Pharmaceuticals, Inc. (AVEO)
About AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.87M | 6.02M | 28.80M | 5.41M | 7.58M | 2.52M | 19.02M | 18.12M | 1.29M | 19.29M | 164.85M | 44.68M | 20.72M | 19.66M | 11.03M |
| Cost of Revenue | 4.74M | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 34.14M | 4.77M | 28.80M | 5.41M | 7.58M | 2.52M | 19.02M | 18.12M | 1.29M | 19.29M | 164.85M | 44.68M | 20.72M | 19.66M | 11.03M |
| Gross Profit Ratio | 87.81% | 79.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 26.30M | 22.68M | 17.96M | 20.65M | 25.18M | 23.70M | 12.88M | 38.25M | 68.47M | 91.36M | 101.74M | 86.35M | 51.79M | 41.82M | 29.25M |
| General & Administrative | 0.00 | 22.22M | 11.21M | 10.78M | 9.14M | 8.21M | 14.22M | 18.59M | 28.71M | 36.93M | 29.17M | 14.76M | 10.12M | 9.16M | 6.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 60.81M | 22.22M | 11.21M | 10.78M | 9.14M | 8.21M | 14.22M | 18.59M | 28.71M | 36.93M | 29.17M | 14.76M | 10.12M | 9.16M | 6.50M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.36M | 11.73M | 8.02M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 87.11M | 44.90M | 29.17M | 31.43M | 34.32M | 31.91M | 27.09M | 56.84M | 97.18M | 128.29M | 130.90M | 101.11M | 61.91M | 50.99M | 35.75M |
| Cost & Expenses | 91.85M | 44.90M | 29.17M | 31.43M | 34.32M | 31.91M | 27.09M | 56.84M | 97.18M | 128.29M | 130.90M | 101.11M | 61.91M | 50.99M | 35.75M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.00K | 32.00K | 125.00K | 497.00K | 527.00K | 126.00K | 144.26K | 1.17M | 2.17M |
| Interest Expense | -4.05M | 1.61M | 1.82M | 2.19M | 2.37M | 1.95M | 2.31M | 2.39M | 3.13M | 3.50M | 3.84M | 3.39M | 2.81M | 2.09M | 2.44M |
| Depreciation & Amortization | -7.83M | 21.00K | 11.58M | 22.22M | -33.74M | 30.00K | 9.57M | 6.22M | 3.78M | 2.51M | 1.65M | 1.35M | 1.29M | 1.32M | 1.33M |
| EBITDA | -57.39M | -33.96M | 11.20M | -3.14M | -62.55M | -24.81M | -3.13M | -44.13M | -100.13M | -108.38M | 36.14M | -54.05M | -40.09M | -29.07M | -21.21M |
| EBITDA Ratio | -147.62% | -564.18% | 38.91% | -58.01% | -825.32% | -986.36% | -16.44% | -243.51% | -7,743.77% | -561.98% | 21.92% | -120.97% | -193.52% | -147.84% | -192.22% |
| Operating Income | -49.55M | -38.88M | -374.00K | -25.36M | -28.81M | -29.39M | -12.43M | -50.45M | -103.90M | -111.64M | 33.95M | -56.43M | -41.19M | -31.33M | -24.72M |
| Operating Income Ratio | -127.47% | -645.90% | -1.30% | -468.79% | -380.14% | -1,168.71% | -65.32% | -278.37% | -8,035.89% | -578.85% | 20.59% | -126.28% | -198.83% | -159.33% | -223.99% |
| Total Other Income/Expenses | -3.79M | 3.29M | 9.76M | 20.03M | -36.11M | 2.61M | -2.58M | -2.29M | -3.13M | -2.76M | -3.30M | -2.36M | -3.00M | -1.15M | -266.03K |
| Income Before Tax | -53.34M | -35.58M | 9.39M | -5.33M | -64.92M | -26.79M | -15.00M | -52.74M | -107.03M | -114.39M | 30.65M | -58.79M | -44.19M | -32.47M | -24.98M |
| Income Before Tax Ratio | -137.22% | -591.19% | 32.60% | -98.52% | -856.63% | -1,065.05% | -78.85% | -291.01% | -8,277.57% | -593.15% | 18.59% | -131.57% | -213.30% | -165.17% | -226.40% |
| Income Tax Expense | 7.83M | 4.90M | 0.00 | 0.00 | 101.00K | 101.00K | -268.00K | 98.00K | 2.00K | 744.00K | 537.00K | 1.03M | -100.06K | 937.81K | 2.17M |
| Net Income | -61.18M | -35.58M | 9.39M | -5.33M | -65.03M | -26.89M | -15.00M | -52.74M | -107.03M | -114.39M | 30.65M | -58.79M | -44.09M | -32.47M | -24.98M |
| Net Income Ratio | -157.37% | -591.19% | 32.60% | -98.52% | -857.96% | -1,069.07% | -78.85% | -291.01% | -8,277.57% | -593.15% | 18.59% | -131.57% | -212.82% | -165.17% | -226.40% |
| EPS | -2.86 | -1.66 | 0.61 | -0.41 | -6.14 | -3.88 | -2.69 | -10.09 | -21.02 | -26.37 | 7.72 | -22.98 | -22.31 | -202.07 | -155.46 |
| EPS Diluted | -2.86 | -1.66 | 0.61 | -0.41 | -6.14 | -3.88 | -2.69 | -10.09 | -21.02 | -26.37 | 7.39 | -22.98 | -22.31 | -202.07 | -155.46 |
| Weighted Avg Shares Out | 21.40M | 21.40M | 15.38M | 13.07M | 10.59M | 6.93M | 5.57M | 5.23M | 5.09M | 4.34M | 3.97M | 2.56M | 1.98M | 160.70K | 160.70K |
| Weighted Avg Shares Out (Dil) | 21.40M | 21.40M | 15.38M | 13.07M | 10.59M | 6.93M | 5.57M | 5.23M | 5.09M | 4.34M | 4.15M | 2.56M | 1.98M | 160.70K | 160.70K |
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q1 2021 Results - Earnings Call Transcript
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock
Can AVEO (AVEO) Run Higher on Strong Earnings Estimate Revisions?
AVEO: Drug Approved, But Still A Long Way To Go Before Self Sufficiency
AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Lags Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports